Evaluation of fluticasone propionate/salmeterol for the treatment of COPD: a systematic review

References

• GOLD. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for diagnosis, management, and prevention of COPD – 2020 Report; 2020 [cited 2020 Mar 7]. Available from: https://goldcopd.org/wp-content/uploads/2019/12/GOLD-2020-FINAL-ver1.2-03Dec19_WMV.pdf
   Google Scholar
• US Food and Drug Administration. ADVAIR DISKUS (fluticasone propionate and salmeterol inhalation powder), for oral inhalation use. Reference ID: 4372031; 2000 [cited 2019 Oct 14]. Available from: www.accessdata.fda.gov/drugsatfda_docs/label/2019/021077s061lbl.pdf
   Google Scholar
• European Medicines Agency. Seretide Diskus, EMEA/306065/2006; 2006 [cited 2019 Oct 14]. Available from: www.ema.europa.eu/en/medicines/human/referrals/seretide-diskus
   Google Scholar
• GOLD. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for diagnosis,, and prevention of COPD – 2006 Report; 2006 [cited 2019 Oct 14]. Available from: https://www.who.int/respiratory/copd/GOLD_WR_06.pdf
   Google Scholar
• Wilkie M, Finch S, Schembri S. inhaled corticosteroids for chronic obstructive pulmonary disease–the shifting treatment paradigm. COPD. 2015;12(5):582–590.
   PubMedGoogle Scholar
• Casas A, Montes de Oca M, Menezes AM, et al. Respiratory medication used in COPD patients from seven Latin American countries: the LASSYC study. Int J Chron Obstruct Pulmon Dis. 2018;13:1545–1556.
   PubMed Web of Science ®Google Scholar
• Bogart M, Stanford RH, Reinsch T, et al. Clinical characteristics and medication patterns in patients with COPD prior to initiation of triple therapy with ICS/LAMA/LABA: A retrospective study. Respir Med. 2018 Sep;142:73–80.
   PubMed Web of Science ®Google Scholar
• Tavakoli H, Johnson KM, FitzGerald JM, et al. Trends in prescriptions and costs of inhaled medications in chronic obstructive pulmonary disease: a 19-year population-based study from Canada. Int J Chron Obstruct Pulmon Dis. 2019;14:2003–2013.
   PubMed Web of Science ®Google Scholar
• Gruffydd-Jones K, Brusselle G, Jones R, et al. Changes in initial COPD treatment choice over time and factors influencing prescribing decisions in UK primary care: a real-world study. NPJ Prim Care Respir Med. 2016;26(1):1–7.
   Google Scholar
• Haughie S, Allan R, Wood N, et al. Equivalent systemic exposure to fluticasone propionate/salmeterol following single inhaled doses from advair diskus and wixela inhub: results of three pharmacokinetic bioequivalence studies. J Aerosol Med Pulm Drug Deliv. 2020 Feb;33(1):34–42.
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. WIXELATM INHUBTM (fluticasone propionate and salmeterol inhalation powder), for oral inhalation use; 2019 [cited 2019 Oct 18]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/208891Orig1s000lbl.pdf
   Google Scholar
• Moher D, Shamseer L, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015 Jan 1;4:1.
   PubMed Web of Science ®Google Scholar
• Schardt C, Adams MB, Owens T, et al. Utilization of the PICO framework to improve searching PubMed for clinical questions. BMC Med Inform Decis Mak. 2007 Jun;15(7):16.
   Google Scholar
• Higgins JPT, Green S. Cochrane handbook for systematic reviews of interventions version 5.1.0. The Cochrane Collaboration. 16.1.2 General principles for dealing with missing data; 2011 [updated 2011 Mar]. Available from https://handbook-5-1.cochrane.org/chapter_16/16_1_2_general_principles_for_dealing_with_missing_data.htm
   Google Scholar
• European Commission. A guideline on summary of product characteristics (SmPC); 2009 [cited 2017 Jun 22]. Available from: http://ec.europa.eu/health//sites/health/files/files/eudralex/vol-2/c/smpc_guideline_rev2_en.pdf
   Google Scholar
• Abràmoff MD, Magalhães PJ, Ram SJ. Image processing with ImageJ. Biophotonics Int. 2004;11(7):36–42.
   Google Scholar
• Sullivan KM, Dean A, Soe MM. OpenEpi: a web-based epidemiologic and statistical calculator for public health. 433021. 2009;124(3):471.
   Google Scholar
• Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996 Feb;17(1):1–12.
   PubMedGoogle Scholar
• NCT00355342. Bone mineral density study in patients with chronic obstructive pulmonary disease. DISKUS® Inhaler is a Trademark of the GSK Group of Companies; 2006 [cited 2019 Sep 26].
   Google Scholar
• Saito T, Takeda A, Hashimoto K, et al. Triple therapy with salmeterol/fluticasone propionate 50/250 plus tiotropium bromide improve lung function versus individual treatments in moderate-to-severe Japanese COPD patients: a randomized controlled trial - Evaluation of Airway sGaw after treatment with tripLE. Int J Chron Obstruct Pulmon Dis. 2015;10:2393–2404.
   PubMed Web of Science ®Google Scholar
• NCT01751113. A 3 way cross-over study evaluating the effects of ADOAIR twice daily plus tiotropium bromide once daily compared with the individual treatments of japanese subjects (SCO116572); 2012 [cited 2019 Sep 26].
   Google Scholar
• Magnussen H, Disse B, Rodriguez-Roisin R, et al. Withdrawal of inhaled glucocorticoids and exacerbations of COPD. N Engl J Med. 2014 Oct 2;371(14):1285–1294.
   PubMed Web of Science ®Google Scholar
• NCT00975195. Inhaled corticosteroid withdrawal in patients with chronic obstructive pulmonary disease; 2009 [cited 2019 Sep 26].
   Google Scholar
• Rossi A, van der Molen T, Del Olmo R, et al. INSTEAD: a randomised switch trial of indacaterol versus salmeterol/fluticasone in moderate COPD. Eur Respir J. 2014 Dec;44(6):1548–1556.
   PubMed Web of Science ®Google Scholar
• NCT01555138. Comparison of indacaterol 150 mcg once daily (o.d.) with salmeterol/fluticasone propionate 50 mcg/500 mcg twice daily (b.i.d.) (INSTEAD); 2012 [cited 2019 Sep 26].
   Google Scholar
• Maltais F, Mahler DA, Pepin V, et al. Effect of fluticasone propionate/salmeterol plus tiotropium versus tiotropium on walking endurance in COPD. Eur Respir J. 2013 Aug;42(2):539–541.
   PubMed Web of Science ®Google Scholar
• NCT01124422. Fluticasone propionate/salmeterol combination 250/50 DISKUS in the exercise endurance time in patients with chronic obstructive pulmonary disease (ESWT); 2010 [cited 2019 Sep 26].
   Google Scholar
• Watkins ML, Wilcox TK, Tabberer M, et al. Shortness of Breath with Daily Activities questionnaire: validation and responder thresholds in patients with chronic obstructive pulmonary disease. BMJ Open. 2013 Oct 22;3(10):e003048.
   PubMed Web of Science ®Google Scholar
• NCT00984659. Validation of a new shortness of breath with daily activities questionnaire in patients with chronic obstructive pulmonary disease; 2009 [cited 2019 Sep 26].
   Google Scholar
• Betsuyaku T, Kato M, Fujimoto K, et al. A randomized trial of symptom-based management in Japanese patients with COPD. Int J Chron Obstruct Pulmon Dis. 2018;13:2409–2423.
   PubMed Web of Science ®Google Scholar
• NCT01762800. Evaluating the control of COPD symptoms in patients treated with tiotropium bromide 18mcg once daily alone, ADOAIR 50/250mcg twice daily alone or ADOAIR 50/250mcg plus tiotropium bromide 18mcg; 2013 [cited 2019 Sep 26].
   Google Scholar
• Magnussen H, Paggiaro P, Schmidt H, et al. Effect of combination treatment on lung volumes and exercise endurance time in COPD. Respir Med. 2012 Oct;106(10):1413–1420.
   PubMed Web of Science ®Google Scholar
• NCT00530842. Effect of tiotropium plus salmeterol vs. fluticasone/salmeterol on static lung volumes and exercise endurance in COPD; 2007 [cited 2019 Sep 26].
   Google Scholar
• Dransfield MT, Cockcroft JR, Townsend RR, et al. Effect of fluticasone propionate/salmeterol on arterial stiffness in patients with COPD. Respir Med. 2011 Sep;105(9):1322–1330.
   PubMed Web of Science ®Google Scholar
• NCT00857766. A 16-week study to evaluate the effect of advair DISKUS™ 250/50mcg on arterial stiffness in subjects with chronic obstructive pulmonary disease (COPD); 2009 [cited 2019 Sep 26].
   Google Scholar
• Koser A, Westerman J, Sharma S, et al. Safety and efficacy of fluticasone propionate/salmeterol hydrofluoroalkane 134a metered-dose-inhaler compared with fluticasone propionate/salmeterol diskus in patients with chronic obstructive pulmonary disease. Open Respir Med J. 2010 Oct 21;4:86–91.
   PubMedGoogle Scholar
• NCT00633217. Advair HFA for chronic obstructive pulmonary disease(COPD); 2008 [cited 2019 Sep 26].
   Google Scholar
• Partridge MR, Schuermann W, Beckman O, et al. Effect on lung function and morning activities of budesonide/formoterol versus salmeterol/fluticasone in patients with COPD. Ther Adv Respir Dis. 2009 Aug;3(4):1–11.
   PubMedGoogle Scholar
• NCT00542880. Evaluation of onset of effect in patients with severe chronic obstructive pulmonary disease (COPD) treated with symbicort® compared to seretide® (SPEED); 2007 [cited 2019 Sep 26].
   Google Scholar
• NCT00784550. A 24-week study to evaluate the safety and efficacy of ADVAIR DISKUS® inhaler 250/50mcg plus SPIRIVA HANDIHALER® inhaler versus SPIRIVA HANDIHALER® inhaler plus Placebo DISKUS® inhaler in subjects with chronic obstructive pulmonary disease (COPD). (ADC111114); 2008 [cited 2019 Sep 26].
   Google Scholar
• Chapman KR, Hurst JR, Frent SM, et al. Long-term triple therapy de-escalation to indacaterol/glycopyrronium in patients with chronic obstructive pulmonary disease (SUNSET): a randomized, double-blind, triple-dummy clinical trial. Am J Respir Crit Care Med. 2018 Aug 1;198(3):329–339.
   PubMed Web of Science ®Google Scholar
• NCT02603393. Evaluation of the efficacy and safety of QVA149 (110/50 μg o.d.) vs tiotropium (18 µg o.d.) + salmeterol/fluticasone propionate FDC (50/500 µg b.i.d.) in patients with moderate to severe COPD; 2015 [cited 2019 Sep 26].
   Google Scholar
• Frith PA, Ashmawi S, Krishnamurthy S, et al. Efficacy and safety of the direct switch to indacaterol/glycopyrronium from salmeterol/fluticasone in non‐frequently exacerbating COPD patients: the FLASH randomized controlled trial. Respirology. 2018;23(12):1152–1159.
   PubMed Web of Science ®Google Scholar
• NCT02516592. Assessment of switching from salmeterol/fluticasone to indacaterol/glycopyrronium in a symptomatic COPD patient cohort (FLASH); 2015 [cited 2019 Sep 26].
   Google Scholar
• Ohar JA, Crater GD, Emmett A, et al. Fluticasone propionate/salmeterol 250/50 mug versus salmeterol 50 mug after chronic obstructive pulmonary disease exacerbation. Respir Res. 2014 Sep 24;15:105.
   PubMed Web of Science ®Google Scholar
• NCT01110200. Chronic obstructive pulmonary disease (COPD) post-hospitalization study; 2010 [cited 2019 Sep 26].
   Google Scholar
• NCT02055352. Study to evaluate efficacy/safety of combination budesonide/indacaterol vs fluticasone/salmeterol in patients with COPD (COMBINE); 2014 [cited 2019 Sep 26].
   Google Scholar
• Hagedorn C, Kassner F, Banik N, et al. Influence of salmeterol/fluticasone via single versus separate inhalers on exacerbations in severe/very severe COPD. Respir Med. 2013 Apr;107(4):542–549.
   PubMed Web of Science ®Google Scholar
• NCT00527826. Influence of salmeterol xinafoate/fluticasone propionate (50/500 µg BID) on the course of the disease and exacerbation frequency in COPD patients gold stage III and IV; 2007 [cited 2019 Sep 26].
   Google Scholar
• NCT00974246. The effect on depressive symptoms in ECF residents with COPD (DISK-02); 2009 cited 2019 Sep 26.
   Google Scholar
• Betsuyaku T, Kato M, Fujimoto K, et al. A study to assess COPD symptom-based management and to optimise treatment strategy in Japan (COSMOS-J) based on GOLD 2011. Int J Chron Obstruct Pulmon Dis. 2013;8:453–459.
   PubMed Web of Science ®Google Scholar
• Leidy NK, Wilcox TK, Jones PW, et al. Development of the EXAcerbations of chronic obstructive pulmonary disease tool (EXACT): a patient-reported outcome (PRO) measure. Value Health. 2010 Dec;13(8):965–975.
   PubMed Web of Science ®Google Scholar
• Davit BM, Nwakama PE, Buehler GJ, et al. Comparing generic and innovator drugs: a review of 12 years of bioequivalence data from the United States Food and Drug Administration. Ann Pharmacother. 2009 Oct;43(10):1583–1597.
   PubMed Web of Science ®Google Scholar
• Lavorini F, Ninane V, Haughney J, et al. Switching from branded to generic inhaled medications: potential impact on asthma and COPD. Expert Opin Drug Deliv. 2013 Dec;10(12):1597–1602.
   PubMed Web of Science ®Google Scholar
• Calzetta L, Matera MG, Braido F, et al. Withdrawal of inhaled corticosteroids in COPD: a meta-analysis. Pulm Pharmacol Ther. 2017 Aug;45:148–158.
   PubMed Web of Science ®Google Scholar
• Calzetta L, Di Marco F, Blasi F, et al. Impact of ICS/LABA and LABA/LAMA FDCs on functional and clinical outcomes in COPD: a network meta-analysis. Pulm Pharmacol Ther. 2019 Oct;19:101855.
   Google Scholar
• Di Marco F, Sotgiu G, Santus P, et al. Long-acting bronchodilators improve exercise capacity in COPD patients: a systematic review and meta-analysis. Respir Res. 2018 Jan 24;19(1):18.
   PubMedGoogle Scholar
• Cazzola M, Rogliani P, Calzetta L, et al. Triple therapy versus single and dual long-acting bronchodilator therapy in COPD: a systematic review and meta-analysis. Eur Respir J. 2018 Dec;52(6):1801586.
   Web of Science ®Google Scholar
• Calzetta L, Cazzola M, Matera MG, et al. Adding a LAMA to ICS/LABA therapy: a meta-analysis of triple combination therapy in COPD. Chest. 2019 Apr;155(4):758–770.
   PubMed Web of Science ®Google Scholar
• Zheng Y, Zhu J, Liu Y, et al. Triple therapy in the management of chronic obstructive pulmonary disease: systematic review and meta-analysis. Bmj. 2018;363:k4388.
   PubMedGoogle Scholar
• Vanfleteren L, Fabbri LM, Papi A, et al. Triple therapy (ICS/LABA/LAMA) in COPD: time for a reappraisal. Int J Chron Obstruct Pulmon Dis. 2018;13:3971–3981.
   PubMed Web of Science ®Google Scholar
• Kardos P, Worsley S, Singh D, et al. Randomized controlled trials and real-world observational studies in evaluating cardiovascular safety of inhaled bronchodilator therapy in COPD. Int J Chron Obstruct Pulmon Dis. 2016;11:2885–2895.
   PubMedGoogle Scholar
• Pahus L, Burgel PR, Roche N, et al. Randomized controlled trials of pharmacological treatments to prevent COPD exacerbations: applicability to real-life patients. BMC Pulm Med. 2019 Jul 12;19(1):127.
   PubMedGoogle Scholar
• Cazzola M, Rogliani P. Do we really need asthma–chronic obstructive pulmonary disease overlap syndrome? J Allergy Clin Immunol. 2016;138(4):977–983.
   PubMed Web of Science ®Google Scholar
• GINA. Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention; 2019 [cited 2020 Feb 6]. Available from: https://ginasthma.org/wp-content/uploads/2019/06/GINA-2019-main-report-June-2019-wms.pdf
   Google Scholar
• Ess SM, Schneeweiss S, Szucs TD. European healthcare policies for controlling drug expenditure. Pharmacoeconomics. 2003;21(2):89–103.
   PubMed Web of Science ®Google Scholar
• Simoens S, De Coster S. Sustaining generic medicines markets in Europe. J Generic Med. 2006;3(4):257–268.
   Google Scholar
• King DR, Kanavos P. Encouraging the use of generic medicines: implications for transition economies. Croat Med J. 2002;43(4):462–469.
   PubMed Web of Science ®Google Scholar
• Dunne SS, Dunne CP. What do people really think of generic medicines? A systematic review and critical appraisal of literature on stakeholder perceptions of generic drugs. BMC Med. 2015;13(1):173.
   PubMedGoogle Scholar